Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer

Koppikar, Smruti; Oaknin, Ana; Babu, K Govind; Lorusso, Domenica; Gupta, Sudeep; Rajabto, Wulyo; Harano, Kenichi; Hong, Shaodong; Malik, Rozita Abdul; Strebel, Heinrik Martin Jude S.; Aggarwal, Ieera Madan; Chen, Lai; Dejthevaporn, Thitiya; Tangjitgamol, Siriwan; Cheng, Wen‐Fang; Chay, Wen Yee; Benavides, Doris R.; Hashim, Najihah Mohd; Moon, Yong Wha; Yunokawa, Mayu; Anggraeni, Tricia Dewi; Wen, Wei; Curigliano, Giuseppe; Maheshwari, Amita; Mahantshetty, Umesh; Sheshadri, Suma; Peters, Sheila Annie; Yoshino, Takayuki; Pentheroudakis, George

doi:10.1016/j.esmoop.2022.100774

Cited by 12 publications

(7 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ECs were classified into four categories based on the genomewide, transcriptomic and DNA methylation data, including (1) POLE hyper-mutated, (2) MSI-H (microsatellite instable-high) or mismatch repair-deficient (dMMR), (3) microsatellite stability (MSS) or low-copy numbers, (4) p53-abnormal or high-copy type (1). Investigators have further simplified it to ProMisE typing by combining clinical practice and the feasibility of pathological testing, namely POLE-mutated, MSI-H/dMMR, p53 wild-type and p53-abnormal (2)(3)(4). The catalytic subunit of DNA polymerase ϵ (POLE), repairing mistakes during DNA replication, is one of the critical molecular biomarkers in ECs (2).…”

Section: Introductionmentioning

confidence: 99%

Immune signatures of the POLE mutation in endometrial carcinomas: a systematic study based on TCGA data and clinical cohort validation

Wang,

Yu,

Wang

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundPOLE is a critical biomarker for endometrial cancer (ECs) prognosis and therapeutic decision. However, the immune infiltration and immunotherapy-related gene expression in the tumor microenvironment (TME) of POLE-mutated ECs remain unresolved.MethodsThe TCGA database was used to characterize the TME of POLE mutants, which primarily included immune cells and co-expression genes. We used immunohistochemistry (IHC) to determine immune cell abundance and PD-L1 expression in 104 EC tissues, including 11 POLE mutants and 93 wild-type.ResultsThe bioinformatic study found significant differences in gene expression of the chemokine family, immune-cell markers, and lysozyme in POLE mutants, along with immune response activation. In POLE-mutated ECs, the abundance of CD4+T, CD8+T, M1 macrophages, and dendritic cells increased considerably. Furthermore, POLE mutations may enhance immune cell recruitment or activation and lymphocyte homing in ECs. POLE mutants also had increased expression of immune-checkpoint suppressor genes such as PD-L1, CTLA-4, TIM-3, and others. The tumor mutation burden (TMB) was higher in ECs with POLE mutation. In the validation cohort, we discovered that POLE mutations were related to the immune infiltration abundance of CD8+, CD4+, and Foxp3+ cells and PD-L1 expression by IHC. The prognosis of TCGA-ECs showed that the survival time of the CD8, CD4, PD-L1, or Foxp3 over-expression subgroup of the POLE mutants was significantly prolonged compared to the down-regulation subgroup or the POLE wild-type.ConclusionThe infiltration abundance of CD8+ T, CD4+ T, Foxp3+ T cells, and the expression of PD-L1 harbor crucial value for the prognosis or individualized therapy of POLE-mutated ECs.

show abstract

Section: Introductionmentioning

confidence: 99%

Immune signatures of the POLE mutation in endometrial carcinomas: a systematic study based on TCGA data and clinical cohort validation

Wang,

Yu,

Wang

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Even though the prognosis of colorectal cancer is frequently poor with a median overall survival (OS) of 5-6 months, the survival time may be extended with combination treatment methods (3,4). The current therapeutic algorithm for metastatic colorectal cancer (mCRC) management from the National Comprehensive Cancer Network (5) and European Society For Medical Oncology (6) may involve a combination of different therapies which are tailored to the individual, based on the type and timing of prior therapy and the toxicity profiles of essential drugs. The main treatment approach includes systemic therapy and radical resection, if possible, often in conjunction with the local treatment of primary and metastatic sites.…”

Section: Introductionmentioning

confidence: 99%

“…Evaluation of the KRAS/NRAS and BRAF mutation status, as well as HER2 amplifications and microsatellite instability/mismatch repair status are recommended for patients with mCRC (5). In addition to systemic therapy, locally ablative procedures or resection may be considered in cases of liver or lung oligometastases (6). However, as brain metastases are rare, there is a lack of data concerning the detection and management of this type of metastasis.…”

Section: Introductionmentioning

confidence: 99%

Management of brain metastasis from rectal cancer using whole‑brain radiation therapy followed by bevacizumab and chemotherapy: A case report

Nguyen,

Phung,

Nguyen

et al. 2023

Oncol Lett

View full text Add to dashboard Cite

Brain metastases in colorectal cancer are uncommon, which has resulted in a shortage of data concerning their screening and management. Multiple therapeutic modalities with chemotherapy, chemoradiation and targeted therapy, including bevacizumab and cetuximab regimens, have shown promising results. The present study describes the case of a 47-year-old male, diagnosed with T4N2M1 rectal cancer who underwent systemic therapy with modified FOLFOXIRI and cetuximab. The patient achieved a complete clinical response after 12 cycles. Following the discontinuation of cetuximab, the patient was given capecitabine as a maintenance therapy and subsequently developed brain metastasis. The patient received whole-brain radiation therapy (WBRT) followed by a bevacizumab plus FOLFIRI regimen. The patient showed a good response as revealed by cranial magnetic resonance imaging, with a reduction in lesion size and no sign of cerebral edema. In addition, the patient maintained a stable neurological condition for >10 months. These findings suggest that the early detection of brain metastases requires the close monitoring of neurological symptoms. In addition, WBRT followed by bevacizumab and chemotherapy is a potential management plan for brain metastasis from rectal cancer.

show abstract

“…The treatment of TNBC is aimed at inhibiting the growth of the primary tumor and metastasis to distant organs (Baranova, et al, 2022). TNBC therapy relies on surgical modalities and neoadjuvant/adjuvant chemotherapy (Kepmenkes RI, 2018;Koppikar, et al, 2023).…”

Section: Introductionmentioning

confidence: 99%

Ethanol Extract of Artocarpus odoratissimus (Tarap) Bark Inhibit Migration of MDA-MB-231 Triple Negative Breast Cancer Cells

Rachmi,

Hasanah,

Irawiraman

et al. 2023

Indones J Cancer Chemoprevent

View full text Add to dashboard Cite

Breast cancer is the most diagnosed cancer in the world, with triple negative breast cancer (TNBC) being one of its subtypes that exhibits an aggressive clinical course, a tendency for early metastasis, and a poor prognosis. Tarap (Artocarpus odoratissimus Blanco) is an endemic plant of East Kalimantan, which possesses anticancer potential. This study aimed to explore the ability of ethanol extract of Tarap bark (EETB) in reducing cell viability, inducing apoptosis and inhibiting migration of MDA-MB-231 cells. Cell viability was observed by 3-(4.5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. EETB -induced apoptosis was analyzed by double staining allophycocyanin (APC) Annexin V with PI kit through flow cytometry. Cell migration was determined through scratch assay. EETB was found to decrease cell viability with an IC50 value of 1607.302 μg/ml (R=0.369). EETB’s ability to induce total apoptosis did not show significant differences across various concentrations. EETB was able to inhibit cell migration, especially at concentrations of 800 mg/ml, both at 24-h and 48-h observations. This finding demonstrates that EETB has a weak effect on reducing the viability and inducing the apoptosis of MDA-MB-231 cells. EETB induced morphological cells type change in to globular type and significantly inhibits two-dimensional migration of MDA-MB-231 cells.Keywords: Tarap, Artocarpus odoratissimus, triple negative breast cancer.

show abstract

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer

Cited by 12 publications

References 90 publications

Immune signatures of the POLE mutation in endometrial carcinomas: a systematic study based on TCGA data and clinical cohort validation

Immune signatures of the POLE mutation in endometrial carcinomas: a systematic study based on TCGA data and clinical cohort validation

Management of brain metastasis from rectal cancer using whole‑brain radiation therapy followed by bevacizumab and chemotherapy: A case report

Ethanol Extract of Artocarpus odoratissimus (Tarap) Bark Inhibit Migration of MDA-MB-231 Triple Negative Breast Cancer Cells

Contact Info

Product

Resources

About